close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Silence Therapeutics Plc - American Depository Share (NQ:SLN)

19.73 +0.01 (+0.05%)
Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silence Therapeutics Plc - American Depository Share

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026
From Silence Therapeutics plc
Via Business Wire
News headline image
Halper Sadeh LLC is Investigating Whether BWMN, HZO, SLN are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Silence Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silence Therapeutics plc - SLN
From Kahn Swick & Foti, LLC
Via Business Wire
Nasdaq Session Unusual Volume Movers: Gainers and Decliners ↗
Via Chartmill
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Silence Therapeutics plc (Nasdaq – SLN), Option Care Health, Inc. (Nasdaq – OPCH), RXO Inc. (NYSE – RXO), Sangoma Technologies Corporation (Nasdaq – SANG)
From Brodsky & Smith LLC
Via GlobeNewswire
Today's Top US Stock Movers: Small-Cap Gainers and Losers ↗
Via Chartmill
Today's Top Market Movers: Silence Therapeutics Jumps 126%, CL Workshop Slides 43% ↗
Via Chartmill
Gap-Up and Gap-Down Movers for Oct. 19, 2026 ↗
Via Chartmill
News headline image
SLN Stock Alert: Halper Sadeh LLC is Investigating Whether Silence Therapeutics plc is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Participate in Three September Investor Conferences
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial ↗
Silence Therapeutics (NASDAQ:SLN) reported top-line results from its Phase II SANRECO trial of divesiran in patients with phlebotomy-dependent polycythemia vera, or PV, with the study meeting its... 
Via MarketBeat
News headline image
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
From Silence Therapeutics plc
Via Business Wire
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Participate in Jefferies Global Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
From Silence Therapeutics plc
Via Business Wire
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
Via Chartmill
Top movers in Thursday's session ↗
Via Chartmill
Monday's session: gap up and gap down stocks ↗
Via Chartmill
Here are the top movers in Monday's session. ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.